# Estée Lauder (EL) — InvestMoat Analysis

_Last analyzed: August 19, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/el_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 46 |
| Growth trajectory | 62 |
| Valuation | 72 |
| **Composite** | **57** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** EL
- **Market Cap:** ~$36B

## Moat

Largest pure-play prestige beauty conglomerate (La Mer, Clinique, Estée Lauder, MAC, Tom Ford, Jo Malone) with deep brand portfolio — moat real and less strained than a year ago after four consecutive organic-growth quarters, Mainland China/Japan/Korea share gains, and Jo Malone London plus TOM FORD joining the billion-dollar-brand list. Makeup is still the soft spot (FY26 sales virtually flat) and Korean/Chinese competitive pressure has not gone away.

### The Prestige Brand Portfolio Moat

Estée Lauder's moat is **a portfolio of prestige beauty brands with global distribution scale** — durable in theory, currently repairing:

- **Prestige Brand Heritage:** La Mer, Estée Lauder, Tom Ford, Jo Malone, MAC, Clinique remain one of the deepest prestige portfolios globally. Jo Malone London and TOM FORD crossed into billion-dollar brands in FY26, taking the list to six. Brand heritage and pricing power persist — La Mer still holds $300+ price points; fragrance (Le Labo, TOM FORD, KILIAN PARIS) delivered double-digit organic growth and led the FY26 recovery.
- **Global Distribution Footprint:** Distribution scale across department stores, travel retail, specialty (Sephora, Ulta), Amazon (13 brands / 11 markets) and TikTok Shop (12 brands / 9 markets) is a competitive advantage smaller prestige players cannot match. FY26 posted net sales growth in every geographic region; Mainland China, Japan and Korea all took prestige share in Q4, and M·A·C launched in select U.S. Sephora doors.
- **M&A and Brand Building Track Record:** EL has a long track record of acquiring and scaling prestige brands (Tom Ford, Jo Malone, Bobbi Brown, La Mer, Deciem/The Ordinary). Capital allocation is turning more constructive — remaining Forest Essentials interest (subject to approval), minority stakes in XINÚ and 111Skin — though makeup brands (Bobbi Brown, Too Faced) still need work.

**Moat verdict:** Estée Lauder's moat is brand + distribution scale, AI-neutral and less strained after four consecutive organic-growth quarters, Q4 share gains in China/Korea/Japan, and two new billion-dollar brands. The thesis is Beauty Reimagined / PRGP execution plus sustained China recovery — FY26 confirmed the direction (organic +3%, OM 11.2%, FY27 OM raised). Makeup remaining flat is the unfinished half. Valuation offers turnaround optionality with less execution risk than in May, after the stock paid up on the print.

### Top competitors

- **L'Oréal (OR.PA):** The largest beauty group, from mass to luxury.
- **LVMH (MC.PA):** Dior and Guerlain fragrance and cosmetics, plus Sephora.
- **Shiseido (4911.T):** Prestige skincare in Asia and travel retail.

## Growth

FY26 organic sales +3% (as-reported +5% to $15.0B) with Q4 organic +5% — the fourth consecutive growth quarter — and adj. operating margin 11.2% (from 8.0%), beating the raised 10.7–11.0% guide. Adj. EPS $2.51 vs $2.35–$2.45 guide. FY27: organic +3–5%, adj. OM raised to 12.7–13.5% from the May prelim of 12.5–13.0%, adj. EPS $3.10–$3.35. Fragrance +10% led; makeup still flat.

- **Revenue CAGR estimate:** 3-6%
- **Primary type:** market share
- **Margin trend:** expanding
- **Key risk (moderate):** If Mainland China and travel-retail momentum stalls after four growth quarters — or makeup share losses to Korean/Chinese prestige brands accelerate — FY27's 3–5% organic / 12.7–13.5% OM view slips and the multiple stays pinned to trough-to-mid-cycle EPS rather than a durable recovery.
- **Drivers:**
  - Asia / Travel Retail Recovery — FY26 net sales growth in every region; Mainland China, Japan and Korea took Q4 prestige share; Korea retail sales accelerated to double-digit in Q4 (stable)
  - PRGP Cost Program — Restructuring approvals concluded June 30, 2026; $1.2B gross benefits at high end of range; vast majority of run-rate still lands FY27 (stable)
  - Brand Portfolio Performance — Q4 organic +5% (4th consecutive growth quarter); FY fragrance +10%; Jo Malone + TOM FORD now billion-dollar brands; makeup virtually flat (accelerating)
- **Score derivation:** Base 61 (3–6% CAGR mid-band) + 2.7 trajectory (PRGP and brand portfolio accelerating; travel-retail/regional mix stable) + 4 margin expansion (OM 8.0% → 11.2% FY26, guided 12.7–13.5% FY27) − 5 China/competitive residual risk = 63. Four consecutive organic-growth quarters and Q4 share gains in China/Korea/Japan are now observed, so they sit in the drivers rather than in severity; remaining downside is whether makeup stays flat and the recovery holds. Re-checked 2026-09-25: "PRGP Cost Program" is a margin or profit line, not a revenue driver (margin is scored once, in marginTrend), so it is held stable. Trajectory 2.7 → 1.3; growth score = 62.

## Valuation

At ~$98 after the Aug 19 print (+12% on the day) EL sits ~11% below the $110 base and ~51% above the $65 bear — still ~65% below 2021 highs. On FY26 adj. EPS ($2.51) the stock screens expensive (~39×), but on FY27 adj. EPS ($3.10–$3.35) it is ~30×, compressing toward the mid-20s on a FY28 normalised mid-cycle EPS path if Beauty Reimagined and PRGP keep delivering.

| Multiple | Value | Note |
| --- | --- | --- |
| Forward P/E (FY26 adj.) | ~39× | Adj. EPS $2.51 printed; trough-to-recovery earnings |
| Forward P/E (FY27 adj.) | ~30× | Guide $3.10–$3.35 (midpoint above ~$3.18 street) |
| Price / Sales (FY26) | ~2.4× | ~$36B mkt cap on $15.0B sales; still a discount to historical prestige-beauty median |
| Dividend Yield | ~1.4% | $508M dividends in FY26; $0.35 quarterly held |
| FCF Yield | ~3.7% | FY26 FCF $1.32B (from $0.67B); OCF $1.77B |

The print confirmed the turnaround the May/August preview was waiting on — and the stock paid up 12% for it. Spot now prices a partial recovery (four growth quarters, OM 11.2%) but not full mid-cycle margins. Margin of safety exists versus prior-cycle highs, not versus a clean mid-cycle multiple on today's EPS. _(as of August 19, 2026)_

## Price scenarios

### Bear — $65

China/travel-retail bounce fades, Korean/Chinese brands keep taking makeup share, PRGP savings disappoint, and the multiple stays ~20× on sub-$3.50 EPS.

- Mainland China retail growth reverts to flat/negative through 2027
- Travel retail stalls after the FY26 regional bounce; airport-channel transitions linger
- PRGP run-rate benefits slip past FY27; adj. OM stuck below 12%

### Base — $110

FY27 delivers company-like +3–5% organic and ~13% adj. OM; FY28 EPS reaches ~$4.50–$5.00 and the multiple holds ~22–24× as the turnaround is treated as durable.

- Regional growth holds; China/Korea/Japan share gains persist even if the rate slows
- Operating margin recovers to ~13% in FY27 on PRGP run-rate as guided
- Fragrance + skincare offset makeup; Clinique/Tom Ford/La Mer/Jo Malone carry mix

### Bull — $155

Full Chinese consumer and travel-retail recovery plus successful PRGP execution drives FY28 EPS to $6.50+ and a quality re-rate toward ~23×.

- Chinese consumer recovery accelerates in 2026–27; travel retail remixes toward prior peak contribution
- Operating margin recovers toward 15–16% by FY29
- M&A reignites with bolt-on Asian and indie prestige brands once the balance sheet flexes

---

InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.